BioCentury reported an uptick in biotech financing tied to JP Morgan Healthcare Conference week, with multiple new funds and financings announced, including activity from Arkin, Lux, a16z and Servier. The report highlights that capital flows into biotechs picked up around investor meetings and corporate presentations. The timing underscores continued investor appetite for biopharma despite macro uncertainty; corporate and VC vehicles announced during conference week can set deal‑making momentum for the quarter. Firms and syndicates noted deal activity ranged from venture rounds to larger collaborations and public financings.